ZEB1 and breast cancer: This process is often referred to as dedifferentiation [13], and has been reported in many cancers, including glioblastoma [14], intestinal tumors [15], melanoma [16], and also in breast cancer, where CSCs arise through an epithelial-mesenchymal transition (EMT)-like process facilitated by the ZEB1 promoter [17].